Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema

JAMA Ophthalmol. 2017 Mar 1;135(3):291. doi: 10.1001/jamaophthalmol.2016.5676.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors
  • Bevacizumab*
  • Diabetic Retinopathy
  • Humans
  • Intravitreal Injections
  • Macular Edema*
  • Off-Label Use
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A
  • Bevacizumab